Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 09/08/19 at 10:28am

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The Swiss firm’s integrity was called into question after it waited until it’s $2.1 million gene therapy had been approved before informing the US regulator of inaccuracies in its data.

In other news, Medicare said it would vocer the costs of CAR-T therapies Kymriah and Yescarta as Roche’s immunotherapy Tecentriq met its primary endpoint in a Phase 3 bladder cancer trial. In another Phase 3 success Eli Lilly’s Emgality showed success in treating migraine. However, Pfizer’s sickle cell drug rivipansel flopped when it came to the late stage trial. For all this and more check out this week’s top 10 on

10. Sanofi ends partnership with Lexicon after release of Phase 3 data

French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes drug Zynquista (sotagliflozin).

9. AI accurately detects subtle signs of atrial fibrillation even in normal tests

A new study from the Mayo Clinic shows that artificial intelligence (AI) can detect signs of atrial fibrillation (AF) in an electrocardiogram (EKG), even if the heart is in a normal rhythm at the time of the test.

8. Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages

Top scientists from some of the UK’s foremost nuclear medicine associations have written a letter to recently-anointed Prime Minister Boris Johnson voicing concerns over the nation’s ability to deliver cancer treatments to patients if the UK crashes out of the EU without a deal.

7. Roche's Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of disease worsening and death in a Phase 3 trial of patients with bladder cancer.

6. Daiichi Sankyo's Turalio becomes first FDA-approved therapy for rare tumour

Daiichi Sankyo has seen Turalio approved by the FDA in the treatment of symptomatic tenosynovial giant cell tumours (TGCT) in adult patients whose disease is associated with severe morbidity or functional limitations and cannot be improved with surgery,  making it the first and only therapy available in the US for this indication.

5. Pfizer's sickle cell drug flops at Phase 3 trial

Pfizer has said its sickle cell drug rivipansel failed to meet its primary endpoint or key secondary endpoints in a Phase 3 trial.

4. Medicare will cover CAR-T therapies in United States

Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and Medicaid services (CMS) said.

3. Lilly's Emgality smashes all Phase 3 endpoints in migraine sub-population

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its primary and secondary endpoints as a preventive treatment for chronic and episodic migraine in patients who have previously failed to control their condition with other migraine medications.

2. NICE reject Clovis Oncology's ovarian cancer drug Rubraca

Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib).

1. Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches